2
Clinical Trials associated with TR128A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of TR128 in Patients With Advanced Solid Tumors
This is a open-label, 3+3 design, dose escalation and expansion, phase I study, to evaluate the safety and tolerability, and to determine the Recommended Phase II Dose (RP2D) of TR128 when administered qd in patients with advanced solid tumors. Up to 5 cohorts of 3-6 patients each will be treated in dose escalation phase of the study. One cycle is 28 days. Dose expansion phase to further evaluate the safety, tolerability and preliminary anti-tumor activity of TR128 at the RP2D.
TR128 治疗晚期实体瘤患者中的安全性、耐受性和药代动力学的Ⅰ期临床试验
[Translation] A Phase I clinical trial to investigate the safety, tolerability and pharmacokinetics of TR128 in patients with advanced solid tumors
评估TR128胶囊单药口服给药在晚期实体瘤患者中的安全性和耐受性,确定剂量限制性毒性(DLT)、最大耐受剂量(MTD)和II期临床试验推荐剂量(RP2D)
[Translation] To evaluate the safety and tolerability of TR128 capsules as a single oral agent in patients with advanced solid tumors, and to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD), and recommended dose for Phase II clinical trials (RP2D)
100 Clinical Results associated with TR128
100 Translational Medicine associated with TR128
100 Patents (Medical) associated with TR128
100 Deals associated with TR128